Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We report two siblings with intractable epilepsy, developmental regression, and progressive cerebellar atrophy due to biallelic variants in the gene CAD. For the affected girl, uridine started at age 5 resulted in dramatic improvements in seizure control and development, cessation of cerebellar atrophy, and resolution of hematological abnormalities. Her older brother had a more severe course and only modest response to uridine started at 14 years old. Treatment of this progressive condition via uridine supplementation provides an example of precision diagnosis and treatment using clear outcome measures and biomarkers to monitor efficacy.

More information Original publication

DOI

10.1002/acn3.51272

Type

Journal article

Publication Date

2021-03-01T00:00:00+00:00

Volume

8

Pages

716 - 722

Total pages

6

Keywords

Aspartate Carbamoyltransferase, Atrophy, Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing), Cerebellar Diseases, Child, Child, Preschool, Developmental Disabilities, Dihydroorotase, Disease Progression, Drug Resistant Epilepsy, Female, Humans, Male, Pedigree, Siblings, Uridine